Timing of Atogepant: Unlocking Migraine Relief Potential

Research Summary

A study published in Cephalalgia explored the effects of the timing of atogepant administration on its effectiveness and tolerability in migraine prevention. Conducted over 12 weeks with 81 participants, the research found that monthly migraine days (MMDs) dropped from 17 to 10, with 60% of patients experiencing at least a 50% reduction. Interestingly, the timing (morning vs. evening) did not impact effectiveness or side effects, although evening users showed a greater reduction in disability scores. Taking atogepant without food led to a more substantial decrease in monthly headache days. Further research is needed to confirm these findings.

Study Details

📄 Title: The chronopharmacology of atogepant in migraine prevention: A real-world evaluation of influence of timing of administration on effectiveness and tolerability.

👥 Research Team: Iannone LF et al.

📚 Published In: Cephalalgia

📅 Publication Date: 2026 Mar

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.